» Articles » PMID: 12694821

Impact of Radiotherapy for High-risk Neuroblastoma: a Children's Cancer Group Study

Overview
Specialties Oncology
Radiology
Date 2003 Apr 16
PMID 12694821
Citations 46
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To assess the effect of local radiation administered to primary disease sites in children with high-risk neuroblastoma.

Materials And Methods: A total of 539 eligible patients were entered on protocol CCG-3891, consisting of chemotherapy, primary surgery, and 10 Gy of external beam radiation therapy (EBRT) to gross residual disease, followed by randomized assignment to continuation chemotherapy (CC) or autologous bone marrow transplantation (ABMT). ABMT patients received total body irradiation (TBI).

Results: Estimated event-free survival and overall survival at 5 years were 25% +/- 2% and 35% +/- 2%, respectively. Estimated 5-year locoregional recurrence rates were 51% +/- 5% and 33% +/- 7% for CC and ABMT patients (p = 0.004). For patients who received 10 Gy of EBRT to the primary, the addition of 10 Gy of TBI and ABMT decreased local recurrence compared with CC (22% +/- 12% and 52% +/- 8%, p = 0.022). EBRT did not increase acute toxicity, except for increased total parenteral nutrition administration.

Conclusions: In combination with EBRT to the primary tumor site, the addition of 10 Gy of TBI as a component of high-dose chemotherapy with ABMT improved local control compared with CC without TBI. Results suggest a dose-response relationship for local EBRT. Short-term toxicity of local EBRT is limited.

Citing Articles

Aurora Kinase A inhibition enhances DNA damage and tumor cell death with I-MIBG therapy in high-risk neuroblastoma.

Kumar P, Koach J, Nekritz E, Mukherjee S, Braun B, Dubois S EJNMMI Res. 2024; 14(1):54.

PMID: 38869684 PMC: 11176152. DOI: 10.1186/s13550-024-01112-7.


Local MRI before and after Tumor Resection in Neuroblastoma: Impact of Residual Disease on Event Free Survival.

Schafer J, Gassenmaier S, Warmann S, Urla C, Frauenfeld L, Flaadt T J Clin Med. 2023; 12(23).

PMID: 38068349 PMC: 10707530. DOI: 10.3390/jcm12237297.


Enhancing the sensitization of neuroblastoma to radiotherapy by the construction of a dual-channel parallel free radicals nanoamplifier.

Zhang W, Li X, Zeng J, Wen X, Zhang C, Zhang Y Mater Today Bio. 2023; 23:100828.

PMID: 37822451 PMC: 10562674. DOI: 10.1016/j.mtbio.2023.100828.


Children's Oncology Group's 2023 blueprint for research: Radiation oncology.

Kalapurakal J, Wolden S, Haas-Kogan D, Laack N, Hua C, Paulino A Pediatr Blood Cancer. 2023; 70 Suppl 6:e30593.

PMID: 37486145 PMC: 10588230. DOI: 10.1002/pbc.30593.


Advancing therapy for neuroblastoma.

Qiu B, Matthay K Nat Rev Clin Oncol. 2022; 19(8):515-533.

PMID: 35614230 DOI: 10.1038/s41571-022-00643-z.